TY - JOUR
T1 - Preoperative Depression Status and 5 Year Metabolic and Bariatric Surgery Outcomes in the PCORnet Bariatric Study Cohort
AU - for the PCORnet Bariatric Study Collaborative
AU - Coughlin, Janelle W.
AU - Nauman, Elizabeth
AU - Wellman, Robert
AU - Coley, R. Yates
AU - McTigue, Kathleen M.
AU - Coleman, Karen J.
AU - Jones, Daniel B.
AU - Lewis, Kristina H.
AU - Tobin, Jonathan N.
AU - Wee, Christina C.
AU - Fitzpatrick, Stephanie L.
AU - Desai, Jay R.
AU - Murali, Sameer
AU - Morrow, Ellen H.
AU - Rogers, Ann M.
AU - Wood, G. Craig
AU - Schlundt, David G.
AU - Apovian, Caroline M.
AU - Duke, Meredith C.
AU - McClay, James C.
AU - Soans, Rohit
AU - Nemr, Rabih
AU - Williams, Neely
AU - Courcoulas, Anita
AU - Holmes, John H.
AU - Anau, Jane
AU - Toh, Sengwee
AU - Sturtevant, Jessica L.
AU - Horgan, Casie E.
AU - Cook, Andrea J.
AU - Arterburn, David E.
AU - Coughlin, Janelle W.
AU - Bennett, Wendy L.
AU - Nauman, Elizabeth
AU - Wellman, Robert
AU - Coley, R. Yates
AU - Anau, Jane
AU - Cook, Andrea J.
AU - Arterburn, David
AU - McTigue, Kathleen M.
AU - Courcoulas, Anita
AU - Toh, Sengwee
AU - Sturtevant, Jessica L.
AU - Horgan, Casie E.
AU - Brown, Jeffrey S.
AU - Coleman, Karen J.
AU - Jones, Daniel B.
AU - Wee, Christina C.
AU - Lewis, Kristina H.
AU - Inge, Thomas
N1 - Funding Information:
Funding: The PCORnet Study reported in this publication was conducted using PCORnet, the National Patient-Centered Clinical Research Network. PCORnet has been developed with funding from the Patient-Centered Outcomes Research Institute (PCORI).
Funding Information:
Dr. Arterburn received travel support from the World Congress for Interventional Therapy for Diabetes and the IFSO Latin America Chapter during the conduct of the study. Dr Courcoulas reports grants from Covidien/Ethicon Johnson & Johnson, during the conduct of the study. Dr Jones reports personal fees from Allurion. Dr. Apovian reports personal fees from Nutrisystem, Zafgen, Sanofi- Aventis, Orexigen, Novo Nordisk, GI Dynamics, Takeda, Scientific Intake, Xeno Biosciences, Rhythm Pharmaceuticals, Eisai, EnteroMedics, and Baria- trix Nutrition outside the submitted work; grants from Orexigen, Aspire Bariatrics, GI Dynamics, Myos, Takeda, the Vela Foundation, the Dr. Robert C. and Veronica Atkins Foundation, Coherence Lab, Energesis, and the National Institutes of Health outside the submitted work; and past ownership of stock in Science-Smart LLC. Dr. Fitzpatrick reports financial support from WW (formerly Weight Watchers) outside the submitted work. Dr. Coleman receives funding from Janssen and the Food and Drug Administration outside the submitted work.
Funding Information:
This study was funded by the PCORI via contract OBS-1505-30683.
Funding Information:
Dr. Arterburn received travel support from the World Congress for Interventional Therapy for Diabetes and the IFSO Latin America Chapter during the conduct of the study. Dr Courcoulas reports grants from Covidien/Ethicon Johnson & Johnson, during the conduct of the study. Dr Jones reports personal fees from Allurion. Dr. Apovian reports personal fees from Nutrisystem, Zafgen, Sanofi- Aventis, Orexigen, Novo Nordisk, GI Dynamics, Takeda, Scientific Intake, Xeno Biosciences, Rhythm Pharmaceuticals, Eisai, EnteroMedics, and Baria- trix Nutrition outside the submitted work; grants from Orexigen, Aspire Bariatrics, GI Dynamics, Myos, Takeda, the Vela Foundation, the Dr. Robert C. and Veronica Atkins Foundation, Coherence Lab, Energesis, and the National Institutes of Health outside the submitted work; and past ownership of stock in Science-Smart LLC. Dr. Fitzpatrick reports financial support from WW (formerly Weight Watchers) outside the submitted work. Dr. Coleman receives funding from Janssen and the Food and Drug Administration outside the submitted work.
Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - Objective: To examine whether depression status before metabolic and bariatric surgery (MBS) influenced 5-year weight loss, diabetes, and safety/utilization outcomes in the PCORnet Bariatric Study. Summary of Background Data: Research on the impact of depression on MBS outcomes is inconsistent with few large, long-term studies. Methods: Data were extracted from 23 health systems on 36,871 patients who underwent sleeve gastrectomy (SG; n=16,158) or gastric bypass (RYGB; n=20,713) from 2005-2015. Patients with and without a depression diagnosis in the year before MBS were evaluated for % total weight loss (%TWL), diabetes outcomes, and postsurgical safety/utilization (reoperations, revisions, endoscopy, hospitalizations, mortality) at 1, 3, and 5 years after MBS. Results: 27.1% of SG and 33.0% of RYGB patients had preoperative depression, and they had more medical and psychiatric comorbidities than those without depression. At 5 years of follow-up, those with depression, versus those without depression, had slightly less %TWL after RYGB, but not after SG (between group difference = 0.42%TWL, P = 0.04). However, patients with depression had slightly larger HbA1c improvements after RYGB but not after SG (between group difference = - 0.19, P = 0.04). Baseline depression did not moderate diabetes remission or relapse, reoperations, revision, or mortality across operations; however, baseline depression did moderate the risk of endoscopy and repeat hospitalization across RYGB versus SG. Conclusions: Patients with depression undergoing RYGB and SG had similar weight loss, diabetes, and safety/utilization outcomes to those without depression. The effects of depression were clinically small compared to the choice of operation.
AB - Objective: To examine whether depression status before metabolic and bariatric surgery (MBS) influenced 5-year weight loss, diabetes, and safety/utilization outcomes in the PCORnet Bariatric Study. Summary of Background Data: Research on the impact of depression on MBS outcomes is inconsistent with few large, long-term studies. Methods: Data were extracted from 23 health systems on 36,871 patients who underwent sleeve gastrectomy (SG; n=16,158) or gastric bypass (RYGB; n=20,713) from 2005-2015. Patients with and without a depression diagnosis in the year before MBS were evaluated for % total weight loss (%TWL), diabetes outcomes, and postsurgical safety/utilization (reoperations, revisions, endoscopy, hospitalizations, mortality) at 1, 3, and 5 years after MBS. Results: 27.1% of SG and 33.0% of RYGB patients had preoperative depression, and they had more medical and psychiatric comorbidities than those without depression. At 5 years of follow-up, those with depression, versus those without depression, had slightly less %TWL after RYGB, but not after SG (between group difference = 0.42%TWL, P = 0.04). However, patients with depression had slightly larger HbA1c improvements after RYGB but not after SG (between group difference = - 0.19, P = 0.04). Baseline depression did not moderate diabetes remission or relapse, reoperations, revision, or mortality across operations; however, baseline depression did moderate the risk of endoscopy and repeat hospitalization across RYGB versus SG. Conclusions: Patients with depression undergoing RYGB and SG had similar weight loss, diabetes, and safety/utilization outcomes to those without depression. The effects of depression were clinically small compared to the choice of operation.
KW - bariatric surgery
KW - cohort
KW - depression
KW - longitudinal
KW - outcomes
KW - psychiatric
KW - psychosocial
UR - http://www.scopus.com/inward/record.url?scp=85149870391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149870391&partnerID=8YFLogxK
U2 - 10.1097/SLA.0000000000005364
DO - 10.1097/SLA.0000000000005364
M3 - Article
C2 - 35058404
AN - SCOPUS:85149870391
SN - 0003-4932
VL - 277
SP - 637
EP - 646
JO - Annals of surgery
JF - Annals of surgery
IS - 4
ER -
